Claris Ventures

About The Fund

Claris Ventures is a venture capital firm that specializes in early stage investments in the biopharmaceutical sector. With an emphasis on bioengineering and life sciences, their goal is to support and finance the most promising ventures that are making strides in addressing critical unmet clinical needs, tackling a range of issues including rare diseases, oncology, immunology, and other life-threatening conditions. They firmly believe in investing in companies that demonstrate solid scientific evidence and have a clear vision that can significantly impact people's lives. Claris Ventures provides not only capital but also a wealth of competence and hands-on support to help initiate and accelerate clinical development programs. Their focus on clinical evidence as the basis for value creation enables them to assist in the translation of breakthrough scientific innovations into therapeutic solutions that benefit patients. With a fund investment ranging from a minimum of $100,000 to a maximum of $5,000,000 and a sweet spot at around $1,500,000, Claris Ventures mainly engages in Seed and Series A funding rounds, positioning themselves as crucial contributors during the critical early stages of company development in the biotech industry. Their portfolio includes companies like Kither Biotech, NeoPhore, Resalis Therapeutics, Heqet Therapeutics, Iama Therapeutics, Sibylla Biotech, Page Therapeutics, Repron Therapeutics, ALKemist Bio, and Lever Bio—each working on groundbreaking solutions for pressing medical challenges. Claris Ventures' support extends beyond monetary investment by offering strategic guidance and expertise, underpinned by collaborative relationships with the European Union's Horizon 2020 Financial Instruments, the European Fund for Strategic Investments, AlpGIP, and the Pan-European Guarantee Fund. Furthermore, they foster a dynamic environment by inviting ideas and talent to join their team to push the frontiers of the biotech sector.